Tag: preclinical
-
Engineered Fluid Devised for Lubricating Joint Cartilage
18 August 2014. Biomedical engineers at Johns Hopkins University in Baltimore developed a synthetic lubrication fluid for natural or artificial joints in the body that emulates the properties of natural substances. A team led by Johns Hopkins medical professor Jennifer Elisseeff published its results earlier this month in the journal Nature Materials (paid subscription required).…
-
Allied Minds, Bristol-Myers Squibb Form Life Science Venture
4 August 2014. Allied Minds, a research commercialization company in Boston, and the pharmaceutical company Bristol-Myers Squibb in New York are starting a joint venture to discover new drug candidates and enterprises from promising life science research in U.S. university labs. Financial terms of the new venture, named Allied-Bristol Life Sciences LLC, were not disclosed.…
-
Fox Foundation Funding Parkinson Drug Discovery Research
25 July 2014. Researchers from Albert Einstein School of Medicine at Yeshiva University in New York are testing compounds for drugs that take on underlying causes of Parkinson’s disease. A $165,000 grant from the Michael J. Fox Foundation for Parkinson’s Research is funding the one year project led by Ana Maria Cuervo and Evripidis Gavathiotis,…
-
Orphan Status Assigned to Kidney Disorder RNA Therapy
21 July 2014. Regulus Therapeutics Inc. in San Diego says the U.S. Food and Drug Administration designated its RNA therapy for Alport syndrome, a rare genetic kidney disease, an orphan drug. The therapy, code-named RG-012, shows promise in preclinical studies, including with lab mice. Alport syndrome affects about 1 in 50,000 newborns, a condition that…
-
Immunocore, Lilly Collaborate on T-Cell Cancer Therapies
16 July 2014. Drug maker Eli Lilly and Company in Indianapolis and Immunocore Ltd., a biotechnology company in Oxford, U.K. are jointly discovering new cancer therapies based on T-cells in the body’s immune system. The deal will pay Immunocore $15 million for each new therapy identified, with additional payments of $10 million for each therapy…
-
Foundation, Biopharm Partner on RNA-Interference Therapy
19 June 2014. Alnylam Pharmaceuticals Inc. in Cambridge, Massachusetts and the Alpha-1 Project in Miami are collaborating on advancing Alnylam’s therapy to treat alpha-1 antitrypsin deficiency, a rare genetic condition responsible for liver disorders and a lung disease similar to chronic obstructive pulmonary disease or COPD. Alpha-1 Project is the for-profit venture division of the…
-
Drug Sensitivity Target Identified for Mesothelioma Therapy
27 May 2014. Researchers at the biopharmaceutical company Verastem Inc. in Cambridge, Massachusetts found the loss of a certain tumor suppressor improves responsiveness to therapies targeting cancer stem cells that treat mesothelioma, an aggressive form of lung cancer. The team led by Verastem’s research director Jonathan Pachter, with colleagues from Fox Chase Cancer Center in…
-
Pfizer, Biotech to Partner on Brown Fat Cell Research
22 May 2014. BioRestorative Therapies Inc. in Jupiter, Florida and the pharmaceutical company Pfizer Inc. in New York are conducting a joint study of human brown fat tissue and cell lines, to discover more about their use as a platform for therapies for type 2 diabetes and obesity. Financial and intellectual property aspects of the…
-
NYU Medical Center Starts Drug Discovery Partnership Program
1 May 2014. New York University’s Langone Medical Center unveiled an initiative to establish more partnerships with drug and biotechnology companies that move initial therapeutic targets into active drug development programs. NYU’s Office of Therapeutics Alliances, says the university, aims to fill the translation gap or “valley of death” between research performed by academic scientists…
-
Janssen, Univ. of Alberta Partner on Diabetes Research
19 March 2014. Janssen Pharmaceutical Companies, a division of Johnson & Johnson, is joining with University of Alberta in Edmonton to fund research on diabetes with commercial potential. The $600,000 fund, with contributions from Janssen and matched by the government of Alberta and Alberta Diabetes Foundation, will support studies on type 1 and type 2…